Abstract Background Pancreatic Cancer is one of the most lethal cancers, with less than 8%
of patients surviving 5 years following diagnosis. The last 40 years have seen only small …

Objective Immunotherapy for the treatment of pancreatic ductal adenocarcinoma (PDAC)
has shown limited efficacy. Poor CD8 T-cell infiltration, low neoantigen load and a highly …

Pancreatic ductal adenocarcinoma (PDAC) being characterized by a pronounced stromal
compartment is commonly diagnosed at an advanced stage limiting curative treatment …

Cancer‐associated fibroblasts (CAF s) are considered the most abundant type of stromal
cells in pancreatic ductal adenocarcinoma (PDAC), playing a critical role in tumour …

Introduction Immune checkpoint inhibitors (ICI), eg, targeting programmed cell death protein
1-ligand 1 (PD-L1) or its receptor PD-1, have markedly improved the therapy of many …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease in urgent need of
improved therapy. A characteristic feature of PDAC is an abundant fibroinflammatory …

Background Pancreatic ductal adenocarcinoma (PDAC) has little response to immune
checkpoint inhibitors. An in-depth understanding of the immune microenvironment from a …

Objective Limited efficacy of immune checkpoint inhibitors in pancreatic ductal
adenocarcinoma (PDAC) has prompted investigation into combination therapy. We …

Background Pancreatic cancer (PC) hijacks innate cellular processes to promote cancer
growth. We hypothesized that PC exploits PD-1/PD-L1 not only to avoid immune responses …

Background The epigenetic mechanisms involved in the progression of pancreatic ductal
adenocarcinoma (PDAC) remain largely unexplored. This study aimed to identify key …